Primary Sclerosing Cholangitis Market is expected to reach US$ 304.32 million by 2032 | Major Companies - Intercept Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb, Johnson & Johnson.

Market Size and Growth:

The Global Primary Sclerosing Cholangitis Market size reached US$ 171 million in 2024 and is expected to reach US$ 304.32 million by 2032, growing with a CAGR of 7.4% during the forecast period 2024-2032.

The Primary Sclerosing Cholangitis Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/primary-sclerosing-cholangitis-market?sz

The Primary Sclerosing Cholangitis (PSC) Market encompasses the development, production, and commercialization of therapies, diagnostics, and treatment solutions for PSC, a chronic liver disease causing inflammation and scarring of bile ducts. It includes pharmaceuticals, biologics, and emerging therapies aimed at slowing disease progression, managing symptoms, and improving patient outcomes, while addressing unmet medical needs in both rare and chronic liver disorder segments.

Recent Key Developments of United States:

✅ November 2025: Chemomab Therapeutics advanced preparations for the Phase 3 trial of nebokitug (CM-101) in PSC patients, building on prior positive Phase 2 data.

✅ November 2025: Mirum Pharmaceuticals completed enrollment in the VISTAS Phase 2b trial of volixibat for PSC, with topline data anticipated in Q2 2026.

✅ October 2025: ProQR received FDA authorization (via CTA alignment) to advance AX-0810, an RNA editing therapy targeting NTCP for primary sclerosing cholangitis (PSC), enabling Phase 1 dosing initiation.

Recent Key Developments of Europe:

✅ December 2025: Year-in-review reports highlighted PSC advances in Europe, including regulatory progress and multinational trial participation amid growing market projections.

✅ October 2025: ProQR obtained EMA authorization (CTA) for the Phase 1 trial of AX-0810 in cholestatic diseases including PSC, conducted in the Netherlands.

List of the Key Players in the Primary Sclerosing Cholangitis Market:

Intercept Pharmaceuticals
Gilead Sciences
Bristol Myers Squibb
Takeda Pharmaceutical Company Limited
Johnson & Johnson
Allergan
Genfit
Pliant Therapeutics
ChemomAb Therapeutics Ltd.
Dr. Falk Pharma

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/primary-sclerosing-cholangitis-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Primary Sclerosing Cholangitis Market:

By Treatment: Medication-based Therapies, Bile Duct Blockages, Liver Transplantation.

By Disease Stage: Early-stage, Moderate-stage, Advanced-stage.

By Patient Age: Child (0-18), Adult (18 and above).

By End-User: Hospitals, Specialty Clinics, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=primary-sclerosing-cholangitis-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Primary Sclerosing Cholangitis market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Primary Sclerosing Cholangitis Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Primary Sclerosing Cholangitis market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Primary Sclerosing Cholangitis Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Primary Sclerosing Cholangitis Market in 2025?
◆ What is the projected growth rate of the Primary Sclerosing Cholangitis Market through 2033?
◆ Who are the key players in the Primary Sclerosing Cholangitis Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.